Although the molecular mechanism underlying the combination treatment needs to be further elucidated, these data provide new insights into NSCLC and BC treatment using a combination with MEK inhibitor and B7-H3-redirected immunotherapy. This evidence concerns the gene MAP2K7 and breast cancer.